Perspectives in allergen immunotherapy: 2019 and beyond

Oliver Pfaar; Ioana Agache; Frédéric de Blay; Sergio Bonini; Adam M. Chaker; Stephen R. Durham; Radoslaw Gawlik; Peter W. Hellings; Marek Jutel; Jörg Kleine-Tebbe; Ludger Klimek; Matthias V. Kopp; Andreas Nandy; Ronald L. Rabin; Ronald van Ree; Harald Renz; Graham Roberts; Anne Marie Salapatek; Carsten B. Schmidt-Weber; Mohamed H. Shamji; Gunter J. Sturm; J. Christian Virchow; Ulrich Wahn; Christoph Willers; Petra Zieglmayer; Cezmi A. Akdis

doi:10.1111/all.14077

Perspectives in allergen immunotherapy: 2019 and beyond

Oliver Pfaar, Ioana Agache, Frédéric de Blay, Sergio Bonini, Adam M. Chaker, Stephen R. Durham, Radoslaw Gawlik, Peter W. Hellings, Marek Jutel, Jörg Kleine-Tebbe, Ludger Klimek, Matthias V. Kopp, Andreas Nandy, Ronald L. Rabin, Ronald van Ree, Harald Renz, Graham Roberts, Anne Marie Salapatek, Carsten B. Schmidt-Weber, Mohamed H. ShamjiGunter J. Sturm, J. Christian Virchow, Ulrich Wahn, Christoph Willers, Petra Zieglmayer, Cezmi A. Akdis

Chair of Molecular allergology and Environment

Research output: Contribution to journal › Review article › peer-review

121 Scopus citations

Abstract

The seventh “Future of the Allergists and Specific Immunotherapy (FASIT)” workshop held in 2019 provided a platform for global experts from academia, allergy clinics, regulatory authorities and industry to review current developments in the field of allergen immunotherapy (AIT). Key domains of the meeting included the following: (a) Biomarkers for AIT and allergic asthma; (b) visions for the future of AIT; (c) progress and data for AIT in asthma and the updates of GINA and EAACI Asthma Guidelines (separated for house dust mite SCIT, SLIT tablets and SLIT drops; patient populations) including a review of clinically relevant endpoints in AIT studies in asthma; (d) regulatory prerequisites such as the “Therapy Allergen Ordinance” in Germany; (e) optimization of trial design in AIT clinical research; (f) challenges planning and conducting phase III (field) studies and the future role of Allergen Exposure Chambers (AEC) in AIT product development from the regulatory point of view. We report a summary of panel discussions of all six domains and highlight unmet needs and possible solutions for the future.

Original language	English
Pages (from-to)	3-25
Number of pages	23
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	74
Issue number	S108
DOIs	https://doi.org/10.1111/all.14077
State	Published - 1 Dec 2019

Keywords

allergen exposure chamber
allergen immunotherapy
allergic asthma
biomarker
clinical trials

Access to Document

10.1111/all.14077

Cite this

Pfaar, O., Agache, I., de Blay, F., Bonini, S., Chaker, A. M., Durham, S. R., Gawlik, R., Hellings, P. W., Jutel, M., Kleine-Tebbe, J., Klimek, L., Kopp, M. V., Nandy, A., Rabin, R. L., van Ree, R., Renz, H., Roberts, G., Salapatek, A. M., Schmidt-Weber, C. B., ... Akdis, C. A. (2019). Perspectives in allergen immunotherapy: 2019 and beyond. Allergy: European Journal of Allergy and Clinical Immunology, 74(S108), 3-25. https://doi.org/10.1111/all.14077

@article{bc331e741a1b408b8b13d4ab1b1003cf,

title = "Perspectives in allergen immunotherapy: 2019 and beyond",

abstract = "The seventh “Future of the Allergists and Specific Immunotherapy (FASIT)” workshop held in 2019 provided a platform for global experts from academia, allergy clinics, regulatory authorities and industry to review current developments in the field of allergen immunotherapy (AIT). Key domains of the meeting included the following: (a) Biomarkers for AIT and allergic asthma; (b) visions for the future of AIT; (c) progress and data for AIT in asthma and the updates of GINA and EAACI Asthma Guidelines (separated for house dust mite SCIT, SLIT tablets and SLIT drops; patient populations) including a review of clinically relevant endpoints in AIT studies in asthma; (d) regulatory prerequisites such as the “Therapy Allergen Ordinance” in Germany; (e) optimization of trial design in AIT clinical research; (f) challenges planning and conducting phase III (field) studies and the future role of Allergen Exposure Chambers (AEC) in AIT product development from the regulatory point of view. We report a summary of panel discussions of all six domains and highlight unmet needs and possible solutions for the future.",

keywords = "allergen exposure chamber, allergen immunotherapy, allergic asthma, biomarker, clinical trials",

author = "Oliver Pfaar and Ioana Agache and {de Blay}, Fr{\'e}d{\'e}ric and Sergio Bonini and Chaker, {Adam M.} and Durham, {Stephen R.} and Radoslaw Gawlik and Hellings, {Peter W.} and Marek Jutel and J{\"o}rg Kleine-Tebbe and Ludger Klimek and Kopp, {Matthias V.} and Andreas Nandy and Rabin, {Ronald L.} and {van Ree}, Ronald and Harald Renz and Graham Roberts and Salapatek, {Anne Marie} and Schmidt-Weber, {Carsten B.} and Shamji, {Mohamed H.} and Sturm, {Gunter J.} and Virchow, {J. Christian} and Ulrich Wahn and Christoph Willers and Petra Zieglmayer and Akdis, {Cezmi A.}",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors. Allergy published by John Wiley & Sons Ltd",

year = "2019",

month = dec,

day = "1",

doi = "10.1111/all.14077",

language = "English",

volume = "74",

pages = "3--25",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "S108",

}

Pfaar, O, Agache, I, de Blay, F, Bonini, S, Chaker, AM, Durham, SR, Gawlik, R, Hellings, PW, Jutel, M, Kleine-Tebbe, J, Klimek, L, Kopp, MV, Nandy, A, Rabin, RL, van Ree, R, Renz, H, Roberts, G, Salapatek, AM, Schmidt-Weber, CB, Shamji, MH, Sturm, GJ, Virchow, JC, Wahn, U, Willers, C, Zieglmayer, P & Akdis, CA 2019, 'Perspectives in allergen immunotherapy: 2019 and beyond', Allergy: European Journal of Allergy and Clinical Immunology, vol. 74, no. S108, pp. 3-25. https://doi.org/10.1111/all.14077

TY - JOUR

T1 - Perspectives in allergen immunotherapy

T2 - 2019 and beyond

AU - Pfaar, Oliver

AU - Agache, Ioana

AU - de Blay, Frédéric

AU - Bonini, Sergio

AU - Chaker, Adam M.

AU - Durham, Stephen R.

AU - Gawlik, Radoslaw

AU - Hellings, Peter W.

AU - Jutel, Marek

AU - Kleine-Tebbe, Jörg

AU - Klimek, Ludger

AU - Kopp, Matthias V.

AU - Nandy, Andreas

AU - Rabin, Ronald L.

AU - van Ree, Ronald

AU - Renz, Harald

AU - Roberts, Graham

AU - Salapatek, Anne Marie

AU - Schmidt-Weber, Carsten B.

AU - Shamji, Mohamed H.

AU - Sturm, Gunter J.

AU - Virchow, J. Christian

AU - Wahn, Ulrich

AU - Willers, Christoph

AU - Zieglmayer, Petra

AU - Akdis, Cezmi A.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The seventh “Future of the Allergists and Specific Immunotherapy (FASIT)” workshop held in 2019 provided a platform for global experts from academia, allergy clinics, regulatory authorities and industry to review current developments in the field of allergen immunotherapy (AIT). Key domains of the meeting included the following: (a) Biomarkers for AIT and allergic asthma; (b) visions for the future of AIT; (c) progress and data for AIT in asthma and the updates of GINA and EAACI Asthma Guidelines (separated for house dust mite SCIT, SLIT tablets and SLIT drops; patient populations) including a review of clinically relevant endpoints in AIT studies in asthma; (d) regulatory prerequisites such as the “Therapy Allergen Ordinance” in Germany; (e) optimization of trial design in AIT clinical research; (f) challenges planning and conducting phase III (field) studies and the future role of Allergen Exposure Chambers (AEC) in AIT product development from the regulatory point of view. We report a summary of panel discussions of all six domains and highlight unmet needs and possible solutions for the future.

AB - The seventh “Future of the Allergists and Specific Immunotherapy (FASIT)” workshop held in 2019 provided a platform for global experts from academia, allergy clinics, regulatory authorities and industry to review current developments in the field of allergen immunotherapy (AIT). Key domains of the meeting included the following: (a) Biomarkers for AIT and allergic asthma; (b) visions for the future of AIT; (c) progress and data for AIT in asthma and the updates of GINA and EAACI Asthma Guidelines (separated for house dust mite SCIT, SLIT tablets and SLIT drops; patient populations) including a review of clinically relevant endpoints in AIT studies in asthma; (d) regulatory prerequisites such as the “Therapy Allergen Ordinance” in Germany; (e) optimization of trial design in AIT clinical research; (f) challenges planning and conducting phase III (field) studies and the future role of Allergen Exposure Chambers (AEC) in AIT product development from the regulatory point of view. We report a summary of panel discussions of all six domains and highlight unmet needs and possible solutions for the future.

KW - allergen exposure chamber

KW - allergen immunotherapy

KW - allergic asthma

KW - biomarker

KW - clinical trials

UR - http://www.scopus.com/inward/record.url?scp=85077081957&partnerID=8YFLogxK

U2 - 10.1111/all.14077

DO - 10.1111/all.14077

M3 - Review article

C2 - 31872476

AN - SCOPUS:85077081957

SN - 0105-4538

VL - 74

SP - 3

EP - 25

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - S108

ER -

Perspectives in allergen immunotherapy: 2019 and beyond

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this